AQP1

Aquaporin-1

Score: 0.625 Price: $0.62 Low Druggability Status: active Wiki: AQP1
🧠 Neurodegeneration
HYPOTHESES
1
PAPERS
26
KG EDGES
125
DEBATES
0

3D Protein Structure

🧬 AQP1 — PDB 1J4N Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability
Low
Score: 0.39
Clinical Stage
Approved
Target Class
Ion Channel
Safety
0.50
Druggability Analysis
Drug Development0.75
Structural Tractability0.70
Target Class0.85
Safety Profile0.50
Key Metrics
PDB Structures:
3
Known Drugs:
1
Approved:
1
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Approved
Therapeutic Areas:
Cerebral edema Acute ischemic stroke Traumatic brain injury Neurotoxic brain swelling Glaucoma (aqueous humor regulation) Neurodegenerative diseases with edema component
Druggability Rationale: AQP1 represents a promising druggable target for neurodegeneration due to its role in water transport and potential involvement in neuroinflammatory processes. The availability of high-resolution structural data and existing inhibition strategies like acetazolamide suggest potential for targeted therapeutic intervention, with the channel's precise structural characterization enabling rational drug design approaches. The AlphaFold prediction and multiple PDB structures provide a robust structural framework for understanding potential small molecule binding mechanisms.
Mechanism: AQP1 functions as a water channel protein facilitating transmembrane water flux, with emerging evidence suggesting its involvement in neuroinflammatory processes and potential contribution to neuronal cell volume regulation and edema formation in neurodegenerative conditions. In the context of neurodegeneration, AQP1 may modulate neuronal and glial cell responses to oxidative stress, inflammation, and cellular metabolic perturbations, making it a potential strategic target for therapeutic intervention.
Drug Pipeline (1 compounds)
1 Approved
Known Drugs:
Acetazolamide (approved) — Glaucoma, epilepsy, altitude sickness
Structural Data:
PDB (3) ✓AlphaFold ✓Cryo-EM ✓
6POJ7W7R7W7S
UniProt: A0A024RA31
Binding Pocket Analysis:

The water-conducting pore features a narrow selectivity filter (~3 Å diameter) with conserved asparagine-proline-alanine (NPA) motifs that coordinate water molecules; modulators likely bind at the pore entrance or allosteric sites flanking the central channel. High-resolution structural data (PDB: 6POJ, 7W7R, 7W7S) enables structure-based design targeting the extracellular or intracellular vestibules where gating can be modulated.

🧬 3D Protein Structure

🧬 AQP1 — PDB 1J4N Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

AQP1 selectivity is challenging due to the high sequence homology across the aquaporin family (AQP0-AQP12), which could lead to off-target modulation of other water channels. However, structural divergence in the selectivity filter and C-terminus regions provides opportunities for isoform-selective inhibitors to minimize effects on aquaporins involved in other physiological processes.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (6)

Relevant trials from ClinicalTrials.gov

Active
1
Completed
3
Total Enrollment
449
By Phase
EARLY_PHASE1: 1 · PHASE1: 1 · PHASE3: 1 · PHASE4: 3
Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) Recruiting
PHASE3 NCT05707442 n=74
Idiopathic Intracranial Hypotension, Venous Sinus Stenosis
Interventions: Stent Implantation, Acetazolamide-based medical therapy, Weight loss
Sponsor: Beijing Tiantan Hospital | Started: 2023-02-16
Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude Completed
PHASE4 NCT03165890 n=78
Chronic Obstructive Pulmonary Disease (C
Interventions: ACETAZOLAMIDE oral capsule, Placebo oral capsule
Sponsor: University of Zurich | Started: 2017-05-24
Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide Completed
PHASE4 NCT05023941 n=252
Acute Mountain Sickness
Interventions: Acetazolamide, Doctormate® (twice daily for 6 days), Doctormate® (forth daily for 3 days)
Sponsor: Ji Xunming,MD,PhD | Started: 2021-12-01
Impact of Acetazolamide in Reducing Referred Postoperative Pain Completed
PHASE1 NCT04470843 n=33
Prostate Cancer, Men
Interventions: Acetazolamide, Placebo
Sponsor: Medical College of Wisconsin | Started: 2018-08-22
A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning Withdrawn
EARLY_PHASE1 NCT03806751
Validation of a New Noninvasive Method t
Interventions: [O-15]Water, Acetazolamide
Sponsor: University of Alabama at Birmingham | Started: 2025-02-01
Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption Unknown
PHASE4 NCT02371473 n=12
Central Sleep Apnea, Secondary
Interventions: Acetazolamide-placebo, Placebo-acetazolamide
Sponsor: Shahid Beheshti University of Medical Sciences | Started: 2014-11

Linked Hypotheses (1)

Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus0.431

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Portfolio 0.65 (25%) Druggability 0.39 (20%) Evidence 0.54 (20%) Safety 0.50 (15%) Competitive 0.40 (10%) Connectivity 0.90 (10%) 0.625 composite

Knowledge Graph (20)

associated with (4)

AQP1 neurodegeneration
AQP1 AQP4
AQP1 CFTR
AQP1 GAT1

co discussed (9)

AQP1 KCNK2
AQP1 GJA1
AQP1 HCRTR2
AQP1 LOXL1-4
AQP1 HCRTR1
...and 4 more

expressed in (1)

AQP1 AQP4

implicated in (1)

AQP1 neurodegeneration

inhibits (3)

AQP1 HDAC4
AQP1 MEF2A
AQP1 AQP4

regulates (1)

AQP1 CFTR

transports (1)

AQP1 GAT1

Debate History (0)

No debates yet